Everything below concerns GHRH analogue. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-03-18. Numbers and descriptions here follow the published literature rather than marketing material.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
| Property | Value | Notes |
|---|---|---|
| Duration with linker | Several days | Reported in early human work |
| Duration without linker | Tens of minutes | Short plasma residence |
| Albumin attachment site | Cysteine-34 | Covalent maleimide reaction |
| Primary receptor | Pituitary GHRH receptor | Stimulates growth hormone release |
| Downstream marker | Insulin-like growth factor 1 | Indirect measure of activity |
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
=== Regulation of intracellular signaling pathways === TGA1 also regulates intracellular signaling pathways that control tumor-associated behaviors. In retinoblastoma, ITGA1 promotes proliferation, migration, and colony formation through the activation of STAT3 signaling. ITGA1 inhibition decreases STAT3 expression, phosphorylated STAT3 activity, STAT3 nuclear localization, and focal adhesion kinase (FAK) signaling. Restoring STAT3 activity partially recovers the effects of ITGA1 suppression. Transcriptomic analysis of ITGA1-inhibited retinoblastoma cells showed altered regulation of genes involved in focal adhesion, ECM-receptor interactions, integrin signaling, and JAK-STAT pathways, indicating that ITGA1 works as a regulator of multiple signaling networks.
== Signs and symptoms == The various types of VWD present with varying degrees of bleeding tendency, usually in the form of easy bruising, nosebleeds, and bleeding gums. Women may experience heavy menstrual periods and blood loss during childbirth. Symptoms of VWD vary depending on age, sex, and VWD type. In children, bruising and nosebleeds are common symptoms. In adults, easy bruising, heavy menstrual bleeding, and bleeding from minor wounds are more common. Sixty to eighty percent of people with VWD have excessive bleeding after surgery or dental extractions. Gastrointestinal bleeding from dilated blood vessels lining the gut (angiodysplasia) can result in severe, lifethreatening gastrointestinal bleeding. This most commonly occurs in seniors with type 2 or 3 VWD. Von Willebrand factor levels normally increase with age, so disease severity often decreases with older age. In women with VWD, 80% have heavy menstrual bleeding with 20% requiring removal of the uterus (hysterectomy). Due to its association with heavy menstrual bleeding, VWD is more commonly diagnosed in women. Women with VWD may also experience heavy bleeding after delivery (postpartum bleeding). Severe internal bleeding and bleeding into joints are rare in those with VWD, but they are more common in those with the more severe type 3 disease. Bleeding in the brain or spinal cord is exceedingly rare in all 3 types of VWD.
7.4.2.1 ABC-type polar-amino-acid transporter The expected taxonomic range for this enzyme is: Eukaryota, Bacteria. The enzyme, found in bacteria, interacts with an extracytoplasmic substrate binding protein and mediates the import of polar amino acids. This entry comprises bacterial enzymes that import Histidine, Arginine, Lysine, Glutamine, Glutamate, Aspartate, ornithine, octopine and nopaline. ATP + H2O + polar amino acid [polar amino acid-binding protein][side 1] = ADP + phosphate + polar amino acid [side 2] + [polar amino acid-binding protein][side1] 7.4.2.2 ABC-type nonpolar-amino-acid transporter The expected taxonomic range for this enzyme is: Eukaryota, Bacteria. The enzyme, found in bacteria, interacts with an extracytoplasmic substrate binding protein. This entry comprises enzymes that import Leucine, Isoleucie and Valine. ATP + H2O + non polar amino acid [non polar amino acid - binding protein][side 1] = ADP + phosphate + non polar amino acid [side 2] + [non polar amino acid - binding protein][side 1] 7.4.2.3 ABC-type mitochondrial protein-transporting ATPase The expected taxonomic range for this enzyme is: Eukaryota, Bacteria. A non-phosphorylated, non-ABC (ATP-binding cassette) ATPase involved in the transport of proteins or preproteins into mitochondria using the TIM (Translocase of the Inner Membrane) protein complex.
Henderson would be executed in the electric chair in the Florida State Prison on April 21, 1993, fourteen months after his arrest. Serial killer David Bullock, suspected in having killed six people with a .38 caliber revolver in one month, from December 5 to January 4, was arrested by the New York Police Department. He would plead guilty to all charges on October 26, commenting "I was in the Christmas spirit. It made me happy." Bullock would be sentenced to 150 years imprisonment. The popular Tamil language film Pokkiri Raja (King of Rogues), an action comedy produced by AVM Saravanan, directed by S. P. Muthuraman and starring Rajinikanth (Shivaji Rao Gaikwad) in two roles, was released in India by Ananda Films. Born: Ireti Osayemi, Nigerian film actress and 2017 Best of Nollywood Award winner for best supporting actress in Ojo Meta (Three Days); in Lagos State Joe Dunthorne, Welsh novelist known for Submarine; in Swansea
Cirrhosis, also known as liver cirrhosis, hepatic cirrhosis, chronic liver failure, chronic hepatic failure, and end-stage liver disease, is a chronic condition of the liver in which the normal functioning tissue, or parenchyma, is replaced with scar tissue (fibrosis) and regenerative nodules as a result of chronic liver disease. Damage to the liver leads to repair of liver tissue and subsequent formation of scar tissue. Over time, scar tissue and nodules of regenerating hepatocytes can replace the parenchyma, causing increased resistance to blood flow in the liver's capillaries—the hepatic sinusoids—and consequently portal hypertension, as well as impairment in other aspects of liver function. The disease typically develops slowly over months or years. Stages include compensated cirrhosis and decompensated cirrhosis. Early symptoms may include tiredness, weakness, loss of appetite, unexplained weight loss, nausea and vomiting, and discomfort in the right upper quadrant of the abdomen. As the disease worsens, symptoms may include itchiness, swelling in the lower legs, fluid build-up in the abdomen, jaundice, bruising easily, and the development of spider-like blood vessels in the skin. The fluid build-up in the abdomen may develop into spontaneous infections. More serious complications include hepatic encephalopathy, bleeding from dilated veins in the esophagus, stomach, or intestines, and liver cancer.
Sources: en.wikipedia.org
The King's College Criteria or the King's College Hospital criteria were devised in 1989 to determine if there were any early indices of poor prognosis in patients with acute liver failure. Acute liver failure is defined as the onset of encephalopathy (altered mental status) or coagulopathy (altered bleeding tendencies) within 26 weeks of a patient diagnosed with liver disease. Patients with hepatitis B acquired at birth, Wilson's disease and autoimmune hepatitis are included if their disease was identified within the past 26 weeks. These patients are very ill, and have a very high risk of dying of their illness without adequate treatment which may include liver transplantation. It is important that physicians find ways of identifying patients with acute liver failure early in their course who will do poorly, and may require liver transplantation. The King's College Criteria have consistently shown excellent operating characteristics for determining prognosis in these patients. As liver transplantation becomes a more accessible option for patients with acute liver failure, the King's College Criteria serve a role in determining which patients may require transplantation.
Adalia Rose Williams, born December 10, 2006, was an American girl with progeria, who was a notable YouTuber and vlogger who shared her everyday life on social media. She died on January 12, 2022, at the age of 15. Amy Foose, born September 12, 1969, was an American girl with progeria, who died at the age of 16 on December 19, 1985. She was the sister of American automobile designer, artist, and TV star Chip Foose, who started a foundation in her name called Amy's Depot. The Progeria Research Foundation gives out The Amy Award every few years, in honor of Amy. Sammy Basso, born December 1, 1995, was an Italian biologist, activist and writer who studied progeria and campaigned to raise awareness of the disease; he died at the age of 28 on October 5, 2024. At the time of his death he was the longest-living survivor of the condition. Tiffany Wedekind, an internet influencer from Columbus, Ohio known as Tenacious Tiffany, is currently the oldest living person with progeria at 49. She also designs clothes, does yoga, involved in public speaking, amongst other things. She credits her positive attitude towards her longevity with the disease. She was also featured on TLC's show One Day In My Body.
A chromatography detector is a device that detects and quantifies separated compounds as they elute from the chromatographic column. These detectors are integral to various chromatographic techniques, such as gas chromatography, liquid chromatography, and high-performance liquid chromatography, and supercritical fluid chromatography among others. The main function of a chromatography detector is to translate the physical or chemical properties of the analyte molecules into measurable signal, typically electrical signal, that can be displayed as a function of time in a graphical presentation, called a chromatograms. Chromatograms can provide valuable information about the composition and concentration of the components in the sample. Detectors operate based on specific principles, including optical, electrochemical, thermal conductivity, fluorescence, mass spectrometry, and more. Each type of detector has its unique capabilities and is suitable for specific applications, depending on the nature of the analytes and the sensitivity and selectivity required for the analysis. There are two general types of detectors: destructive and non-destructive. The destructive detectors perform continuous transformation of the column effluent (burning, evaporation or mixing with reagents) with subsequent measurement of some physical property of the resulting material (plasma, aerosol or reaction mixture). The non-destructive detectors are directly measuring some property of the column eluent (for example, ultraviolet absorption) and thus affords greater analyte recovery.
Lower doses of oral EMP, such as 280 mg/day, have been found to have comparable effectiveness as higher doses but with improved tolerability and reduced toxicity. Doses of 140 mg/day have been described as a very low dosage. EMP has been used at doses of 240 to 450 mg/day intravenously. EMP and other estrogens such as polyestradiol phosphate and ethinylestradiol are far less costly than newer therapies such as GnRH modulators, abiraterone acetate, and enzalutamide. In addition, estrogens may offer significant benefits over other means of androgen deprivation therapy, for instance in terms of bone loss and fractures, hot flashes, cognition, and metabolic status. EMP has been used to prevent the testosterone flare at the start of GnRH agonist therapy in men with prostate cancer.
Sources: en.wikipedia.org
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.
The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.
Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.